Insider Selling: Myovant Sciences Ltd. (NYSE:MYOV) Insider Sells $48,404.40 in Stock

Myovant Sciences Ltd. (NYSE:MYOVGet Rating) insider Ferreira Juan Camilo Arjona sold 4,632 shares of the company’s stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $10.45, for a total value of $48,404.40. Following the sale, the insider now owns 260,129 shares in the company, valued at approximately $2,718,348.05. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Ferreira Juan Camilo Arjona also recently made the following trade(s):

  • On Tuesday, April 5th, Ferreira Juan Camilo Arjona sold 1,922 shares of Myovant Sciences stock. The shares were sold at an average price of $13.78, for a total value of $26,485.16.

NYSE:MYOV opened at $9.38 on Friday. The stock’s 50 day moving average price is $12.73 and its 200 day moving average price is $15.72. The company has a market capitalization of $880.83 million, a PE ratio of -3.80 and a beta of 2.74. Myovant Sciences Ltd. has a 52-week low of $9.18 and a 52-week high of $27.43.

Myovant Sciences (NYSE:MYOVGet Rating) last posted its quarterly earnings data on Wednesday, January 26th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.09). The business had revenue of $54.44 million during the quarter, compared to the consensus estimate of $54.50 million. During the same period last year, the firm earned ($0.82) earnings per share. Equities research analysts predict that Myovant Sciences Ltd. will post -2.18 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Credit Suisse AG lifted its position in Myovant Sciences by 2.3% during the 3rd quarter. Credit Suisse AG now owns 26,642 shares of the company’s stock worth $598,000 after acquiring an additional 587 shares during the period. Torray LLC lifted its position in Myovant Sciences by 0.8% during the 3rd quarter. Torray LLC now owns 74,305 shares of the company’s stock worth $1,667,000 after acquiring an additional 601 shares during the period. Swiss National Bank lifted its position in Myovant Sciences by 1.0% during the 3rd quarter. Swiss National Bank now owns 80,900 shares of the company’s stock worth $1,815,000 after acquiring an additional 800 shares during the period. California State Teachers Retirement System lifted its position in Myovant Sciences by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 31,104 shares of the company’s stock worth $484,000 after acquiring an additional 1,133 shares during the period. Finally, Dark Forest Capital Management LP acquired a new stake in Myovant Sciences during the 3rd quarter worth approximately $32,000. 33.78% of the stock is owned by institutional investors.

A number of research analysts have recently commented on MYOV shares. Zacks Investment Research downgraded Myovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, March 23rd. Robert W. Baird dropped their price objective on Myovant Sciences from $30.00 to $20.00 in a report on Wednesday, April 13th. StockNews.com assumed coverage on Myovant Sciences in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Finally, SVB Leerink dropped their price target on Myovant Sciences from $19.00 to $12.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 13th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $22.00.

Myovant Sciences Company Profile (Get Rating)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.